Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 2/20 | 0.37 |
| ▸ | PPARG | P37231 | 3/20 | 0.36 |
| ▸ | PPARA | Q07869 | 3/20 | 0.36 |
| ▸ | LTA4H | P09960 | 3/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.33 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.33 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.32 |
| ▸ | CTSK | P43235 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1454165 | 0.90 | LTA4H (0.40) | SLC6A4PPARGPPARALTA4HCTSK | |
| SCHEMBL1454220 | 0.85 | POLB (0.36) | SLC6A4PPARGPPARALTA4HPOLB | |
| SCHEMBL7841888 | 0.85 | SLC6A4 (0.43) | SLC6A4PPARGPPARALTA4HPOLB | |
| SCHEMBL1454315 | 0.84 | SLC6A4 (0.36) | SLC6A4PPARGPPARALTA4HPOLB | |
| SCHEMBL11065085 | 0.81 | PPARG (0.44) | SLC6A4PPARGPPARALTA4HKDM4E | |
| SCHEMBL23974956 | 0.78 | PPARG (0.41) | SLC6A4PPARGPPARALTA4HPOLB | |
| SCHEMBL8349925 | 0.78 | SLC6A4 (0.39) | SLC6A4PPARGPPARALTA4HPOLB | |
| SCHEMBL14844285 | 0.78 | LTA4H (0.44) | SLC6A4PPARGPPARALTA4HCTSK | |
| SCHEMBL9770515 | 0.76 | SLC6A4 (0.38) | SLC6A4PPARGPPARALTA4HPOLB | |
| SCHEMBL5050475 | 0.76 | LTA4H (0.44) | SLC6A4PPARGPPARALTA4HALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7910617-B2 | Method for suppressing the number of peripheral blood lymphocytes using an amino alcohol compound | SANKYO COMPANY, LIMITED (JP) | 2011-03-22 | — | — | US | disclosed |
| US-20070191468-A1 | Amino alcohol compound | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2007-08-16 | — | — | US | disclosed |
| EP-1733724-A1 | AMINO ALCOHOL COMPOUND | Sankyo Company, Limited (JP) | 2006-12-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191468-A1 | Amino alcohol compound | ADH1A, ADH1C, BCAT1 | SLC6A4 1912/4885PPARG 388/4885PPARA 295/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.